673 related articles for article (PubMed ID: 25136634)
21. Nano carriers for drug transport across the blood-brain barrier.
Li X; Tsibouklis J; Weng T; Zhang B; Yin G; Feng G; Cui Y; Savina IN; Mikhalovska LI; Sandeman SR; Howel CA; Mikhalovsky SV
J Drug Target; 2017 Jan; 25(1):17-28. PubMed ID: 27126681
[TBL] [Abstract][Full Text] [Related]
22. CNS drug delivery systems: novel approaches.
Pathan SA; Iqbal Z; Zaidi SM; Talegaonkar S; Vohra D; Jain GK; Azeem A; Jain N; Lalani JR; Khar RK; Ahmad FJ
Recent Pat Drug Deliv Formul; 2009 Jan; 3(1):71-89. PubMed ID: 19149731
[TBL] [Abstract][Full Text] [Related]
23. Recent progress of drug nanoformulations targeting to brain.
Khan AR; Yang X; Fu M; Zhai G
J Control Release; 2018 Dec; 291():37-64. PubMed ID: 30308256
[TBL] [Abstract][Full Text] [Related]
24. Vector-mediated drug delivery to the brain.
Temsamani J; Rousselle C; Rees AR; Scherrmann JM
Expert Opin Biol Ther; 2001 Sep; 1(5):773-82. PubMed ID: 11728213
[TBL] [Abstract][Full Text] [Related]
25. Noninvasive nanoparticle strategies for brain tumor targeting.
Sun C; Ding Y; Zhou L; Shi D; Sun L; Webster TJ; Shen Y
Nanomedicine; 2017 Nov; 13(8):2605-2621. PubMed ID: 28756093
[TBL] [Abstract][Full Text] [Related]
26. Targeted drug delivery across the blood brain barrier in Alzheimer's disease.
Rocha S
Curr Pharm Des; 2013; 19(37):6635-46. PubMed ID: 23621533
[TBL] [Abstract][Full Text] [Related]
27. Polymeric nanoparticles - targeted drug delivery systems for treatment of CNS disorders and their possible endocrine disrupting activities.
Rollerova E; Scsukova S; Jurcovicova J; Mlynarcikova A; Szabova E; Kovriznych J; Zeljenkova D
Endocr Regul; 2011 Jan; 45(1):49-60. PubMed ID: 21314211
[TBL] [Abstract][Full Text] [Related]
28. Concepts, technologies, and practices for drug delivery past the blood-brain barrier to the central nervous system.
Crawford L; Rosch J; Putnam D
J Control Release; 2016 Oct; 240():251-266. PubMed ID: 26724368
[TBL] [Abstract][Full Text] [Related]
29. Medicinal chemistry based approaches and nanotechnology-based systems to improve CNS drug targeting and delivery.
Vlieghe P; Khrestchatisky M
Med Res Rev; 2013 May; 33(3):457-516. PubMed ID: 22434495
[TBL] [Abstract][Full Text] [Related]
30. Nanoparticle-Mediated Drug Delivery: Blood-Brain Barrier as the Main Obstacle to Treating Infectious Diseases in CNS.
Gondim BLC; da Silva Catarino J; de Sousa MAD; de Oliveira Silva M; Lemes MR; de Carvalho-Costa TM; de Lima Nascimento TR; Machado JR; Rodrigues V; Oliveira CJF; Cançado Castellano LR; da Silva MV
Curr Pharm Des; 2019; 25(37):3983-3996. PubMed ID: 31612822
[TBL] [Abstract][Full Text] [Related]
31. On the future development of optimally-sized lipid-insoluble systemic therapies for CNS solid tumors and other neuropathologies.
Sarin H
Recent Pat CNS Drug Discov; 2010 Nov; 5(3):239-52. PubMed ID: 20722627
[TBL] [Abstract][Full Text] [Related]
32. Dendrimer advances for the central nervous system delivery of therapeutics.
Xu L; Zhang H; Wu Y
ACS Chem Neurosci; 2014 Jan; 5(1):2-13. PubMed ID: 24274162
[TBL] [Abstract][Full Text] [Related]
33. Getting into the brain: approaches to enhance brain drug delivery.
Patel MM; Goyal BR; Bhadada SV; Bhatt JS; Amin AF
CNS Drugs; 2009; 23(1):35-58. PubMed ID: 19062774
[TBL] [Abstract][Full Text] [Related]
34. Targeting central nervous system pathologies with nanomedicines.
Mizrahy S; Gutkin A; Decuzzi P; Peer D
J Drug Target; 2019; 27(5-6):542-554. PubMed ID: 30296187
[TBL] [Abstract][Full Text] [Related]
35. From naturally-occurring neurotoxic agents to CNS shuttles for drug delivery.
Soddu E; Rassu G; Giunchedi P; Sarmento B; Gavini E
Eur J Pharm Sci; 2015 Jul; 74():63-76. PubMed ID: 25892455
[TBL] [Abstract][Full Text] [Related]
36. A TfR-Binding Cystine-Dense Peptide Promotes Blood-Brain Barrier Penetration of Bioactive Molecules.
Crook ZR; Girard E; Sevilla GP; Merrill M; Friend D; Rupert PB; Pakiam F; Nguyen E; Yin C; Ruff RO; Hopping G; Strand AD; Finton KAK; Coxon M; Mhyre AJ; Strong RK; Olson JM
J Mol Biol; 2020 Jun; 432(14):3989-4009. PubMed ID: 32304700
[TBL] [Abstract][Full Text] [Related]
37. Nanocarriers for the treatment of glioblastoma multiforme: Current state-of-the-art.
Karim R; Palazzo C; Evrard B; Piel G
J Control Release; 2016 Apr; 227():23-37. PubMed ID: 26892752
[TBL] [Abstract][Full Text] [Related]
38. Nanoparticle crossing of blood-brain barrier: a road to new therapeutic approaches to central nervous system diseases.
Ceña V; Játiva P
Nanomedicine (Lond); 2018 Jul; 13(13):1513-1516. PubMed ID: 29998779
[No Abstract] [Full Text] [Related]
39. Nanomedicines for the Treatment of CNS Diseases.
Reynolds JL; Mahato RI
J Neuroimmune Pharmacol; 2017 Mar; 12(1):1-5. PubMed ID: 28150132
[TBL] [Abstract][Full Text] [Related]
40. Brain penetrating peptides and peptide-drug conjugates to overcome the blood-brain barrier and target CNS diseases.
Zhou X; Smith QR; Liu X
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 Jul; 13(4):e1695. PubMed ID: 33470550
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
